Long-term survivors (LTS) in glioblastoma (GBM) patients (pts) homogeneously treated with the Stupp regimen, clinical and molecular characteristics (MGMT and IDH1 status). Initial results from the GLIOCAT study

Date

09 Oct 2016

Session

Poster display

Presenters

Estela Pineda

Citation

Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367

Authors

E. Pineda1, M. Martinez-Garcia2, A. Estival3, M. Gil-Gil4, S. Del Barco5, O. Gallego6, E. Verger7, J. Marruecos8, R. Fuentes8, J. Craven-Bartle Lamote de Grigno9, C. Mesía10, N. García11, F. Alameda12, J.M. Velarde13, T. Pujol14, L. Oleaga14, C. Carrato15, J. Capellades2, S. Villà16, C. Balana11

Author affiliations

  • 1 Medical Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 2 Department Of Medical Oncology, University Hospital del Mar, Barcelona/ES
  • 3 Department Of Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 08916 - Badalona/ES
  • 4 Medical Oncology, Institut Català d'Oncologia Hospital Duran i Reynals, 08908 - Barcelona/ES
  • 5 Medical Oncology, Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona/ES
  • 6 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08026 - Barcelona/ES
  • 7 Radiotherapy, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 8 Radiation Oncology, Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona/ES
  • 9 Radiation Oncology, Hospital de la Santa Creu i Sant Pau, 08026 - Barcelona/ES
  • 10 Medical Oncology, Thoracic Oncology Unit, Institut Català d'Oncologia Hospital Duran i Reynals, 08908 - Barcelona/ES
  • 11 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona/ES
  • 12 Pathology, University Hospital del Mar, Barcelona/ES
  • 13 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, http://cpaper.ctimeetingtech.com/images/_common_blue/48x48/black_arrow.png - Badalona/ES
  • 14 Medical Oncology, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 15 Pathology, Hospital universitari germans trias i pujol, 08916 - Badalona/ES
  • 16 Radiation Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 08916 - Badalona/ES
More

Resources

Background

Prognosis of GBM pts is still poor with a median survival of 15 months; however a small fraction survives more than 30 months, defined in our study as long term survivors (LTS-30).

Methods

We performed a multicenter retrospective and prospective study of newly GBM pts treated with the Stupp Regimen. In the present sub-study we analyze clinical characteristics and molecular factors in LTS-30 compared with pts surviving less than 30 months, including the MGMT and the IDH1 status.

Results

From 2005 to 2014, 432 GBM pts treated with the Stupp Regimen were included with a median progression free survival (mPFS) of 8 months (m) and a median overall survival (mOS) of 14 months, of which 66 (15.3%) were LTS-30, with a mPFS of 24 m and a mOS of 41 m. In this population median karnofsky (KPS) was better (90% vs 80%) with less patients with KPS inferior to 70% (1.9% vs 13.9%; p = 0.006), and median age was also lower (58 vs 62 years) with more pts ≤50 years (34.8% vs 18.3%; p = 0.003). Median OS in patients with IDH1 mutation was 30 m vs 16 m (p = 0.005). Methylated MGMT and mutated IDH1 were significantly more frequent in LTS-30, 75% vs 40.8% (p 

Conclusions

Identifying potential LTS in GBM might be a meaningful endpoint in order to establish the best therapeutic strategy. In our study, methylation status of MGMT is the only independent prognostic factor of LTS-30 in GBM pts treated with Stupp regimen. As expected, patients with LTS-30 are younger with better KPS and with more frequent IDH1 mutation.

Clinical trial identification

Marato Project: 665/C/2013.

Legal entity responsible for the study

IGTP, IDIBELL, Fundacio Parc Salut Mar, Fundacio Clinic

Funding

Marato Project: 665/C/2013

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings